Medicine
Parnate 10 mg tablet
Parnate 10 mg tablet is a prescription medicine containing Tranylcypromine for oral use, marketed by Advanz Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store between 15° and 30°C (59° and 86°F).
Key facts
- Active ingredient (INN)
- Tranylcypromine
- Brand
- Parnate
- Strength
- 10 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 100 tablets
- Marketing authorisation holder
- Advanz Pharma
- Manufacturer
- Advanz Pharma
- Origin register
- US FDA, United States
- Storage
- Store between 15° and 30°C (59° and 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N06AF04 Tranylcypromine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 14 January 2013
- Identifiers
- RxCUI 104838, 313447DailyMed set ID b72d8187-dfcc-4ea0-b5e9-c0be95b69a27NDC 59212-447Application NDA012342
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet, film coated in 1 bottle | 59212-447-10 | Advanz Pharma | 14 January 2013 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 21 February 1961 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Tranylcypromine 10 mg tablet.
Clinical summary
Tranylcypromine is a monoamine oxidase inhibitor indicated for the treatment of major depressive disorder (MDD) in adult patients who have not responded adequately to other antidepressants, among other approved uses. MedsAcross supplies Tranylcypromine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about TranylcypromineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Tranylcypromine Sulfate prescribing information (Actavis Pharma) · U.S. National Library of Medicine, DailyMed
Need Parnate 10 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.